Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forty Seven Raises $75m For Potential 'Universal' CD47 Cancer Therapy

This article was originally published in Scrip

Executive Summary

Forty Seven Inc. has $75m in Series A venture capital and something else that's pretty novel for a startup biotechnology company: an immuno-oncology development program that's already in the clinic with data expected later this year.

Advertisement

Related Content

VC Roundup: More Funds Raise Cash For Biotech; Morphic Closes $51.5m Series A

Topics

Advertisement
UsernamePublicRestriction

Register

SC064634

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel